Related Experiment Videos
Coronary artery bypass surgery in patients with inherited antithrombin deficiency
P Clark1, I D Walker, R F Neilson
1Department of Haematology, Western Infirmary, Glasgow.
Insights
Antithrombin replacement therapy effectively managed patients with inherited antithrombin deficiency during coronary artery bypass grafting. This approach prevented thrombotic and bleeding complications in individuals with a history of thrombosis.
Area of Science:
- Cardiology
- Hematology
- Pharmacology
Background:
- Inherited antithrombin deficiency poses a significant thrombotic risk, particularly during major surgical procedures.
- Coronary artery bypass grafting (CABG) is a high-risk surgery for patients with thrombotic conditions.
- Effective management strategies are crucial for patients with antithrombin deficiency undergoing CABG.
Observation:
- This study describes antithrombin (AT) replacement in three patients with inherited antithrombin deficiency undergoing CABG.
- All patients had a history of thrombotic disease, increasing their perioperative risk.
- AT levels were monitored throughout the bypass and postoperative periods.
Findings:
- Patients achieved satisfactory antithrombin levels during and after CABG with AT replacement therapy.
- Postoperative heparin prophylaxis was administered to all patients.
- No thrombotic or bleeding complications were observed in any of the three patients.
Implications:
- Antithrombin replacement is a viable and safe strategy for managing inherited antithrombin deficiency during CABG.
- This approach can mitigate the risk of thrombosis and bleeding in high-risk surgical patients.
- Further research could explore optimal dosing and long-term outcomes of AT replacement in similar cases.
Abstract:
Antithrombin (AT) replacement in coronary artery bypass grafting procedures in three individuals with inherited antithrombin deficiency is described. All three had a significant personal or family history of thrombotic disease. All patients achieved satisfactory AT levels throughout bypass and in the postoperative period. All received heparin prophylaxis in the postoperative period. None suffered thrombotic or bleeding complications.